Childhood GPA, EGPA, and MPA
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA),...
Gespeichert in:
Veröffentlicht in: | Clinical immunology (Orlando, Fla.) Fla.), 2020-02, Vol.211, p.108325-108325, Article 108325 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 108325 |
---|---|
container_issue | |
container_start_page | 108325 |
container_title | Clinical immunology (Orlando, Fla.) |
container_volume | 211 |
creator | Jariwala, Mehul Laxer, Ronald M. |
description | Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis. |
doi_str_mv | 10.1016/j.clim.2019.108325 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2327383505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521661619305376</els_id><sourcerecordid>2327383505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</originalsourceid><addsrcrecordid>eNp9kF9LwzAUxYMobk6_gIjs0Qdbc5MmacGXMeYUJu5Bn0Ob3LKMdp3JNvDb29rpoy_3H-ccuD9CroHGQEE-rGNTuTpmFLL2kHImTsgQBINIUS5Oj7OUIAfkIoQ1pVQwJs_JgEPKVZKIIbmZrlxlV01jx_Pl5H48-6n5xo5fl5NLclbmVcCrYx-Rj6fZ-_Q5WrzNX6aTRWS4kLtIsRSZMiJhSVZYKYRVPBM0kaaQltKcF5CAKMu0zIEVmIFEqtDydsvAMsNH5K7P3frmc49hp2sXDFZVvsFmHzTjTPGUCypaKeulxjcheCz11rs6918aqO6o6LXuqOiOiu6ptKbbY_6-qNH-WX4xtILHXoDtlweHXgfjcGPQOo9mp23j_sv_BptVbik</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2327383505</pqid></control><display><type>article</type><title>Childhood GPA, EGPA, and MPA</title><source>Elsevier ScienceDirect Journals</source><creator>Jariwala, Mehul ; Laxer, Ronald M.</creator><creatorcontrib>Jariwala, Mehul ; Laxer, Ronald M.</creatorcontrib><description>Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>DOI: 10.1016/j.clim.2019.108325</identifier><identifier>PMID: 31837445</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>ANCA ; ANCA associated vasculitis ; Childhood vasculitis</subject><ispartof>Clinical immunology (Orlando, Fla.), 2020-02, Vol.211, p.108325-108325, Article 108325</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</citedby><cites>FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clim.2019.108325$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31837445$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jariwala, Mehul</creatorcontrib><creatorcontrib>Laxer, Ronald M.</creatorcontrib><title>Childhood GPA, EGPA, and MPA</title><title>Clinical immunology (Orlando, Fla.)</title><addtitle>Clin Immunol</addtitle><description>Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis.</description><subject>ANCA</subject><subject>ANCA associated vasculitis</subject><subject>Childhood vasculitis</subject><issn>1521-6616</issn><issn>1521-7035</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kF9LwzAUxYMobk6_gIjs0Qdbc5MmacGXMeYUJu5Bn0Ob3LKMdp3JNvDb29rpoy_3H-ccuD9CroHGQEE-rGNTuTpmFLL2kHImTsgQBINIUS5Oj7OUIAfkIoQ1pVQwJs_JgEPKVZKIIbmZrlxlV01jx_Pl5H48-6n5xo5fl5NLclbmVcCrYx-Rj6fZ-_Q5WrzNX6aTRWS4kLtIsRSZMiJhSVZYKYRVPBM0kaaQltKcF5CAKMu0zIEVmIFEqtDydsvAMsNH5K7P3frmc49hp2sXDFZVvsFmHzTjTPGUCypaKeulxjcheCz11rs6918aqO6o6LXuqOiOiu6ptKbbY_6-qNH-WX4xtILHXoDtlweHXgfjcGPQOo9mp23j_sv_BptVbik</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Jariwala, Mehul</creator><creator>Laxer, Ronald M.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202002</creationdate><title>Childhood GPA, EGPA, and MPA</title><author>Jariwala, Mehul ; Laxer, Ronald M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>ANCA</topic><topic>ANCA associated vasculitis</topic><topic>Childhood vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jariwala, Mehul</creatorcontrib><creatorcontrib>Laxer, Ronald M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical immunology (Orlando, Fla.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jariwala, Mehul</au><au>Laxer, Ronald M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Childhood GPA, EGPA, and MPA</atitle><jtitle>Clinical immunology (Orlando, Fla.)</jtitle><addtitle>Clin Immunol</addtitle><date>2020-02</date><risdate>2020</risdate><volume>211</volume><spage>108325</spage><epage>108325</epage><pages>108325-108325</pages><artnum>108325</artnum><issn>1521-6616</issn><eissn>1521-7035</eissn><abstract>Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31837445</pmid><doi>10.1016/j.clim.2019.108325</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1521-6616 |
ispartof | Clinical immunology (Orlando, Fla.), 2020-02, Vol.211, p.108325-108325, Article 108325 |
issn | 1521-6616 1521-7035 |
language | eng |
recordid | cdi_proquest_miscellaneous_2327383505 |
source | Elsevier ScienceDirect Journals |
subjects | ANCA ANCA associated vasculitis Childhood vasculitis |
title | Childhood GPA, EGPA, and MPA |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A43%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Childhood%20GPA,%20EGPA,%20and%20MPA&rft.jtitle=Clinical%20immunology%20(Orlando,%20Fla.)&rft.au=Jariwala,%20Mehul&rft.date=2020-02&rft.volume=211&rft.spage=108325&rft.epage=108325&rft.pages=108325-108325&rft.artnum=108325&rft.issn=1521-6616&rft.eissn=1521-7035&rft_id=info:doi/10.1016/j.clim.2019.108325&rft_dat=%3Cproquest_cross%3E2327383505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2327383505&rft_id=info:pmid/31837445&rft_els_id=S1521661619305376&rfr_iscdi=true |